Imrecoxib vs. Celecoxib for Pain Control After Arthroscopic Knee Surgery
Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority studyInflammopharmacology. 2022 Jun;30(3): 875-881.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
One hundred and twenty-six patients undergoing arthroscopic knee surgery were randomized in this non-inferiority trial to receive either imrecoxib (n=64) or celecoxib (n=62). The primary outcome of interest pain scores on a Visual Analog Scale (VAS), measured at rest and during movement up to 72 hours post-operation. Secondary outcomes of interest included pethidine administration, patient satisfa...
Join the Conversation
Please Login or Join to leave comments.